PCR Technologies Market : Emerging Trends, Innovations, Key Industry Insights and Opportunities

Extensive primary research was conducted after acquiring knowledge about the PCR technologies market scenario through secondary research. A significant number of primary interviews were conducted from both the demand (healthcare providers, research institutes, and healthcare professionals) and supply sides (developers, manufacturers, and distributors of PCR technologies products). The primaries interviewed for this study include experts from the PCR technologies products industry (such as CEOs, VPs, directors, sales heads, and marketing managers of tier 1, 2, and 3 companies engaged in offering PCR technologies products and services across the globe) and administrators & purchase managers of hospitals CROs, research institutes, academia, and pharma and biotech companies.

Revenue Growth Analysis:
 
[193 Pages Report] The global PCR technology market is projected to reach USD 9.8 billion by 2025 from USD 7.2 billion in 2020, at a CAGR of 6.3% from 2020 to 2025.
 
Download PDF Brochure:
 https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96291811
 
 Key Factors Driving Market Growth:
 
 The growth of this market is primarily driven by the rising incidences of target diseases and genetic disorders; continuous technological advancements in PCR technologies, the development of miniaturized portable instruments, and incorporation of robotics; increasing investments, funds, and grants for research activities; increasing use of biomarker profiling for disease diagnostics; and the successful completion of the Human Genome Project.
 
dPCR technique to show the highest growth in the PCR technology market during the forecast period
 
The dPCR segment is expected to grow at the highest CAGR in the Polymerace chain reaction market. This is due to ongoing technological developments, growing adoption of dPCR products among key end users (compared with qPCR and other PCR products) across mature markets, continued expansion in the distribution networks of major product manufacturers, and growing private funding for developing and commercializing innovative dPCR instruments. Furthermore, dPCR has many potential applications, including the detection and quantification of low-level pathogens, rare genetic sequences, copy number variations (CNVs), and relative gene expression in single cells are also key factors fuelling the demand growth of dPCR instruments among end users.
 
 By end user, hospitals and diagnostic labs hold the largest market share
 
The hospitals and diagnostic labs segment account for the largest share of the Polymerace chain reaction market. Factors such as the increasing market availability of qPCR reagents in clinical diagnostic applications; ongoing expansion of healthcare infrastructure across emerging countries; high prevalence & incidence of target diseases; and growing awareness are driving the growth of this market segment.
 
Asia Pacific is expected to grow at the highest CAGR in the PCR technology market during the forecast period
 
North America is expected to account for the largest share in the global Polymerace chain reaction market in 2020. However, healthcare infrastructure modernization, increasing penetration of cutting-edge diagnostic technologies (including PCR technologies) for research and clinical applications, growing awareness among physicians and healthcare professionals about the benefits of gene-based disease diagnosis and treatment, and the increasing public-private support to develop novel PCR technologies in Asia Pacific countries have accounted for a particularly high growth rate in this region.
 
 Request Sample Report:
 https://www.marketsandmarkets.com/requestsampleNew.asp?id=96291811 
 
Key Players:
 
As of 2019, the PCR technology market is dominated by Thermo Fisher Scientific, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Germany), and Takara Bio, Inc. (Japan).  Other prominent players in the Polymerace chain reaction market include Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluidigm Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Becton Dickinson and Company (US), Promega Corporation (US), Eppendorf AG (Germany), and Analytik Jena AG (Germany).